April 16 (Reuters) - Johnson & Johnson :
* J&J EXEC SAYS CO HAS DOUBLED MANUFACTURING CAPACITY FOR CELL PROCESSING SINCE BEGINNING OF 2023 - CONF CALL
* J&J EXEC SAYS M&A WILL REMAIN A CRITICAL COMPONENT OF CO'S CAPITAL ALLOCATION STRATEGY
* J&J CEO SAYS "WE HAVE SIGNIFICANT FLEXIBILITY TO CONSIDER MULTIPLE TYPES OF TRANSACTIONS"
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments